Health11 hours ago
Terns Pharmaceuticals Withdraws Oral GLP-1 Weight Loss Drug Following Phase 2 Data
Terns Pharmaceuticals (NASDAQ: TERN) has announced a significant setback in its drug development efforts, deciding to discontinue the oral GLP-1 receptor agonist, TERN-601, intended for weight...